A Phase 2 interventional study of Lenalidomide and Bortezomib in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 36 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.
Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 39th largest by enrollment, is one of 12 that started in 2016, is one of 124 in phase 2, and was the 153rd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
University of Leeds · Sites in United Kingdom
Ages 18+
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
Dickran Kazandjian, MD · Sites in United States
University of Miami · Sites in United States
Ages 18+
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
249 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 67 · Phase 2 164 · Phase 3 47 · Phase 4 10
First in 2002; this study’s year is marked. 12 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 224 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 249 interventional studies. Of the 155 that completed or were terminated, 81 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 249 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 31st largest by enrollment of the 100 interventional ones that give a count, is one of 5 that started in 2016, is one of 32 in phase 2, and was the 67th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
14 of the studies testing lenalidomide in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01863550Phase 3ECOG-ACRIN Cancer Research GroupBortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | 2026-12-31 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 249 studies testing lenalidomide in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the International Myeloma Working Group (IMWG) criteria, by the time of completion of post autologous stem cell transplantation (ASCT) consolidation treatment, compared with RVd alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive lenalidomide, bortezomib, dexamethasone and daratumumab.
Drug: Lenalidomide · Drug: Bortezomib · Drug: Dexamethasone · Drug: Daratumumab
Participants will receive lenalidomide, bortezomib and dexamethasone.
Drug: Lenalidomide · Drug: Bortezomib · Drug: Dexamethasone
Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.
Bortezomib 1.3 mg/m\^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.
Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).
Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.
Percentage of Participants With Stringent Complete Response (sCR)
Percentage of participants who had achieved sCR as determined by the validated computer algorithm according to the International Myeloma Working Group (IMWG) criteria, by the end of post-autologous stem cell transplantation (post-ASCT) consolidation treatment were reported. Complete response (CR) is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and less than (\<) 5 percent (%) PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.
Time frame: From randomization to post-ASCT consolidation (after Cycle 6) before maintenance treatment (up to 10 months)
Percentage of Participants With Complete Response (CR) or Better
CR or better rate is defined as the percentage of participants who achieve CR or sCR, according to the IMWG criteria. CR is negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5% PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry. For 2 participants (1 in each randomized treatment group), data were updated by the study sites which resulted in their inclusion to the response-evaluable analysis set after the primary analysis.
Time frame: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance period of 24 months (overall duration up to 34 months)
Percentage of Participants With Overall Stringent Complete Response (sCR)
Overall sCR rate is defined as the percentage of participants who achieved sCR, according to the IMWG criteria. CR is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5 % PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.
Time frame: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance treatment of 24 months (overall duration up to 34 months)
Percentage of Participants With Overall Response Rate (ORR)
ORR- percentage of participants who achieved partial response (PR) or better (PR, Very Good Partial Response \[VGPR\], CR or sCR) based on computerized algorithm as per IMWG criteria. PR -greater than or equal to (\>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg//24 hours. If serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required. A \>=50% reduction in the size of soft tissue plasmacytomas is also required; VGPR-serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours; CR-negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow. sCR- in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.
Time frame: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance treatment of 24 months (overall duration up to 34 months)
Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better
VGPR or better rate is defined as the percentage of participants who achieved VGPR or better, according to the IMWG criteria. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours.
Time frame: From randomization to end of following: induction treatment, ASCT, post-ASCT consolidation (after Cycle 6) and at the end of maintenance period of 24 months (overall duration up to 34 months)
Percentage of Participants With Negative Minimal Residual Disease (MRD)
Minimal residual disease negative rate is defined as the percentage of participants who achieve MRD negative status by the respective time point. Minimal residual disease was evaluated in participants who achieved CR or sCR (including participants with VGPR or better and suspected daratumumab interference) using next-generation sequencing which utilizes multiple myeloma cell DNA from bone marrow aspirates at a threshold of less than (\<) 10\^5.
Time frame: From randomization to end of following: induction treatment, post-ASCT consolidation (after Cycle 6) (up to 4.5 months), and at the end of maintenance period of 24 months (overall duration up to 34 months)
Duration of Complete Response or Better
Duration of CR or better is the duration from the date of initial documentation of a CR or sCR response, according to the IMWG criteria, to the date of first documented evidence of progressive disease (PR), or relapse from CR. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be greater than or equal to \[\>=\] 0.5 gram per deciliter \[g/dL\] and \>=200 milligrams \[mg\]/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to plasma cells (PCs) proliferative disorder.
Time frame: From randomization to the date of first documented evidence of progressive disease or relapse from CR (up to 5 years)
Duration of Stringent Complete Response (sCR)
Duration of sCR is the duration from the date of initial documentation of a sCR response, according to the IMWG criteria, to the date of first documented evidence of progressive disease, or relapse from sCR. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
Time frame: From randomization to the date of first documented evidence of progressive disease or relapse from sCR (up to 5 years)
Time to Stringent Complete Response (sCR)
Time to sCR is the duration from the date of randomization to the date of initial documentation of sCR, which was confirmed by a repeated measurement as required by the IMWG criteria.
Time frame: From randomization to the date of initial documentation of sCR (up to 5 years)
Time to Complete Response or Better
Time to CR or better is the duration from the date of randomization to the date of initial documentation of CR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.
Time frame: From randomization to the date of initial documentation of CR (up to 5 years)
Time to Very Good Partial Response (VGPR) or Better
Time to VGPR or better is the duration from the date of randomization to the date of initial documentation of VGPR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.
Time frame: From randomization to the date of initial documentation of VGPR or better (up to 5 years)
Time to Partial Response (PR) or Better
Time to PR or better is the duration from the date of randomization to the date of initial documentation of PR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.
Time frame: From randomization to the date of initial documentation of PR or better (up to 5 years)
Progression-free Survival (PFS)
PFS is defined as the duration from the date of randomization to the date of first documented evidence of progressive disease or death, whichever comes first. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
Time frame: From randomization to the date of first documented evidence of progressive disease or death (up to 5 years)
Overall Survival (OS)
OS is measured from the date of randomization to the date of the participant's death.
Time frame: From randomization to the date of initial documentation of participant's death (up to 5 years)
Time to Progression (TTP)
TTP is defined as the duration from the date of randomization to the date of first documented evidence of progressive disease according to the IMWG criteria.
Time frame: From randomization to the date of first documented evidence of progressive disease (up to 5 years)
Duration of Response
Duration of response is defined as the duration from the date of initial documentation of a response (PR or better) according to the IMWG criteria to the date of first documented evidence of progressive disease according to the IMWG criteria. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
Time frame: From the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive (up to 5 years)
223 participants were enrolled/randomized (16 in safety run-in,104 to D-RVd and 103 to RVd group). Among 207 (D-RVd \[104\]+RVd \[103\]) randomized, 201 received treatment (D-RVd: 100 and RVd: 101). 1 participant randomized to D-RVd group received RVd treatment and was randomized twice (resulting a total of 224 participants).
| Milestone | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| Started | 103 | 104 | 16 |
| Treated (safety analysis set) | 101 | 100 | 16 |
| Completed | 76 | 88 | 15 |
| Not completed | 27 | 16 | 1 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 5 | 4 | 1 |
| Withdrew: Withdrawal by subject | 17 | 8 | 0 |
| Withdrew: Other | 4 | 1 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 0 |
| Withdrew: Screen failure | 0 | 2 | 0 |
Percentage of participants who had achieved sCR as determined by the validated computer algorithm according to the International Myeloma Working Group (IMWG) criteria, by the end of post-autologous stem cell transplantation (post-ASCT) consolidation treatment were reported. Complete response (CR) is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and less than (\<) 5 percent (%) PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.
| Percentage of participants | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) |
|---|---|---|
| Percentage of Participants With Stringent Complete Response (sCR) | 32.0 (22.9 to 42.2) | 42.4 (32.5 to 52.8) |
CR or better rate is defined as the percentage of participants who achieve CR or sCR, according to the IMWG criteria. CR is negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5% PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry. For 2 participants (1 in each randomized treatment group), data were updated by the study sites which resulted in their inclusion to the response-evaluable analysis set after the primary analysis.
| Percentage of participants | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| At the end of induction prior to ASCT | 13.4 (7.3 to 21.8) | 19.2 (12.0 to 28.3) | 12.5 (1.6 to 38.3) |
| At the end of ASCT prior to consolidation | 19.6 (12.2 to 28.9) | 27.3 (18.8 to 37.1) | 56.3 (29.9 to 80.2) |
| At the end of post-ASCT consolidation | 42.3 (32.3 to 52.7) | 51.5 (41.3 to 61.7) | 68.8 (41.3 to 89.0) |
| At the end of maintenance period (up to 24 Months) | 60.2 (49.8 to 70.0) | 83.0 (74.2 to 89.8) | 93.8 (69.8 to 99.8) |
Overall sCR rate is defined as the percentage of participants who achieved sCR, according to the IMWG criteria. CR is defined as negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5 % PCs in bone marrow. sCR is defined as in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.
| Percentage of participants | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| At the end of induction prior to ASCT | 7.2 (3.0 to 14.3) | 12.1 (6.4 to 20.2) | 0 (NA to NA) |
| At the end of ASCT prior to consolidation | 14.4 (8.1 to 23.0) | 21.2 (13.6 to 30.6) | 43.8 (19.8 to 70.1) |
| At the end of post-ASCT consolidation | 32.0 (22.9 to 42.2) | 42.4 (32.5 to 52.8) | 56.3 (29.9 to 80.2) |
| At the end of Maintenance Treatment (up to 24 Months) | 48.0 (37.8 to 58.3) | 67.0 (56.9 to 76.1) | 93.8 (69.8 to 99.8) |
ORR- percentage of participants who achieved partial response (PR) or better (PR, Very Good Partial Response \[VGPR\], CR or sCR) based on computerized algorithm as per IMWG criteria. PR -greater than or equal to (\>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg//24 hours. If serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required. A \>=50% reduction in the size of soft tissue plasmacytomas is also required; VGPR-serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours; CR-negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \<5% PCs in bone marrow. sCR- in addition to CR a normal FLC ratio, and absence of clonal PCs by immunohistochemistry or immunofluorescence or 2 to 4-color flow cytometry.
| Percentage of participants | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| At the end of induction prior to ASCT | 91.8 (84.4 to 96.4) | 98.0 (92.9 to 99.8) | 100 (79.4 to 100) |
| At the end of ASCT prior to consolidation | 91.8 (84.4 to 96.4) | 99.0 (94.5 to 100) | 100 (79.4 to 100) |
| At the end of post-ASCT consolidation | 91.8 (84.4 to 96.4) | 99.0 (94.5 to 100) | 100 (79.4 to 100) |
| At the End of Maintenance Treatment (up to 24 Months) | 91.8 (84.5 to 96.4) | 99.0 (94.6 to 100.0) | 100.0 (79.4 to 100.0) |
VGPR or better rate is defined as the percentage of participants who achieved VGPR or better, according to the IMWG criteria. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours.
| Percentage of participants | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| At the end of induction prior to ASCT | 56.7 (46.3 to 66.7) | 71.7 (61.8 to 80.3) | 68.8 (41.3 to 89.0) |
| At the end of ASCT prior to consolidation | 66.0 (55.7 to 75.3) | 86.9 (78.6 to 92.8) | 100 (79.4 to 100) |
| At the end of post-ASCT consolidation | 73.2 (63.2 to 81.7) | 90.9 (83.4 to 95.8) | 100 (79.4 to 100) |
| At the End of Maintenance Period (up to 24 Months) | 77.6 (68.0 to 85.4) | 96.0 (90.1 to 98.9) | 100.0 (79.4 to 100.0) |
Minimal residual disease negative rate is defined as the percentage of participants who achieve MRD negative status by the respective time point. Minimal residual disease was evaluated in participants who achieved CR or sCR (including participants with VGPR or better and suspected daratumumab interference) using next-generation sequencing which utilizes multiple myeloma cell DNA from bone marrow aspirates at a threshold of less than (\<) 10\^5.
| Percentage of participants | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| MRD from randomization to prior to ASCT (10^5) | 7.8 (3.4 to 14.7) | 22.1 (14.6 to 31.3) | 18.8 (4.0 to 45.6) |
| Post ASCT consolidation (10^5) | 20.4 (13.1 to 29.5) | 50.0 (40.0 to 60.0) | 50.0 (24.7 to 75.3) |
| At the End of Maintenance Period (up to 24 Months) (10^5) | 30.1 (21.5 to 39.9) | 64.4 (54.4 to 73.6) | 81.3 (54.4 to 96.0) |
Duration of CR or better is the duration from the date of initial documentation of a CR or sCR response, according to the IMWG criteria, to the date of first documented evidence of progressive disease (PR), or relapse from CR. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be greater than or equal to \[\>=\] 0.5 gram per deciliter \[g/dL\] and \>=200 milligrams \[mg\]/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to plasma cells (PCs) proliferative disorder.
| Months | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| Duration of Complete Response or Better | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Duration of sCR is the duration from the date of initial documentation of a sCR response, according to the IMWG criteria, to the date of first documented evidence of progressive disease, or relapse from sCR. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
| Months | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| Duration of Stringent Complete Response (sCR) | NA (NA to NA) | NA (NA to NA) | NA (42.4 to NA) |
Time to sCR is the duration from the date of randomization to the date of initial documentation of sCR, which was confirmed by a repeated measurement as required by the IMWG criteria.
| Months | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| Time to Stringent Complete Response (sCR) | 14.3 (9.2 to 21.7) | 10.2 (8.8 to 13.0) | 8.4 (7.1 to 15.2) |
Time to CR or better is the duration from the date of randomization to the date of initial documentation of CR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.
| Months | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| Time to Complete Response or Better | 9.6 (8.4 to 12.2) | 8.9 (7.9 to 9.4) | 7.7 (6.7 to 9.7) |
Time to VGPR or better is the duration from the date of randomization to the date of initial documentation of VGPR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.
| Months | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| Time to Very Good Partial Response (VGPR) or Better | 3.0 (2.2 to 6.3) | 2.2 (2.1 to 2.7) | 2.1 (0.9 to 6.7) |
Time to PR or better is the duration from the date of randomization to the date of initial documentation of PR or better, which was confirmed by a repeated measurement as required by the IMWG criteria.
| Months | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| Time to Partial Response (PR) or Better | 0.8 (0.8 to 1.0) | 0.8 (0.8 to 0.8) | 0.8 (0.7 to 1.4) |
PFS is defined as the duration from the date of randomization to the date of first documented evidence of progressive disease or death, whichever comes first. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
| Months | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| Progression-free Survival (PFS) | NA (NA to NA) | NA (NA to NA) | NA (57.6 to NA) |
OS is measured from the date of randomization to the date of the participant's death.
| Months | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
TTP is defined as the duration from the date of randomization to the date of first documented evidence of progressive disease according to the IMWG criteria.
| Months | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| Time to Progression (TTP) | NA (NA to NA) | NA (NA to NA) | NA (57.59 to NA) |
Duration of response is defined as the duration from the date of initial documentation of a response (PR or better) according to the IMWG criteria to the date of first documented evidence of progressive disease according to the IMWG criteria. PD is defined as an increase of 25 % from the lowest response value in one of the following: serum and urine M-component (absolute increase must be \>= 0.5 g/dL and \>=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels (absolute increase must be \> 10 mg/dL); Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.
| Months | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| Duration of Response | NA (NA to NA) | NA (NA to NA) | NA (56.8 to NA) |
Collected over Other adverse events and serious adverse events: up to 30 days after the last dose of study treatment (up to 3 years); All-cause mortality: up to end of study (up to 5 years). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | 7/103 (6.8%) | 53/102 (52%) | 102/102 (100%) |
| Randomized: Daratumumab+RVd (D-RVd) | 7/104 (6.7%) | 46/99 (46.5%) | 99/99 (100%) |
| Safety Run-in: D-RVd | 1/16 (6.3%) | 12/16 (75%) | 16/16 (100%) |
| Event | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| PneumoniaInfections and infestations | 14/102 | 15/99 | 5/16 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/102 | 3/99 | 3/16 |
| PyrexiaGeneral disorders | 10/102 | 11/99 | 1/16 |
| Atrial TachycardiaCardiac disorders | 1/102 | 0/99 | 1/16 |
| Abdominal Pain UpperGastrointestinal disorders | 0/102 | 0/99 | 1/16 |
| NauseaGastrointestinal disorders | 0/102 | 3/99 | 1/16 |
| OesophagitisGastrointestinal disorders | 0/102 | 0/99 | 1/16 |
| VomitingGastrointestinal disorders | 0/102 | 2/99 | 1/16 |
| Cholecystitis AcuteHepatobiliary disorders | 0/102 | 0/99 | 1/16 |
| Escherichia InfectionInfections and infestations | 0/102 | 0/99 | 1/16 |
| Event | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd |
|---|---|---|---|
| LymphopeniaBlood and lymphatic system disorders | 29/102 | 31/99 | 13/16 |
| NeutropeniaBlood and lymphatic system disorders | 41/102 | 63/99 | 13/16 |
| CoughRespiratory, thoracic and mediastinal disorders | 30/102 | 53/99 | 12/16 |
| FatigueGeneral disorders | 63/102 | 71/99 | 10/16 |
| Upper Respiratory Tract InfectionInfections and infestations | 51/102 | 67/99 | 11/16 |
| DiarrhoeaGastrointestinal disorders | 56/102 | 65/99 | 10/16 |
| LeukopeniaBlood and lymphatic system disorders | 30/102 | 39/99 | 10/16 |
| ConstipationGastrointestinal disorders | 42/102 | 51/99 | 6/16 |
| NauseaGastrointestinal disorders | 51/102 | 51/99 | 6/16 |
| ThrombocytopeniaBlood and lymphatic system disorders | 36/102 | 44/99 | 8/16 |
| Age, Continuous(years) | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd | Total |
|---|---|---|---|---|
| Mean | 59 ± 7.27 | 57.2 ± 9.79 | 59.8 ± 5.96 | 58.2 ± 8.49 |
| Sex: Female, Male(Participants) | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd | Total |
|---|---|---|---|---|
| Female | 43 | 46 | 8 | 97 |
| Male | 60 | 58 | 8 | 126 |
| Race/Ethnicity, Customized(Participants) | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 1 | 3 |
| Black or African American | 18 | 14 | 4 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| White | 76 | 85 | 11 | 172 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 5 | 3 | 0 | 8 |
| Other | 1 | 2 | 0 | 3 |
| Region of Enrollment(Participants) | Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) | Randomized: Daratumumab+RVd (D-RVd) | Safety Run-in: D-RVd | Total |
|---|---|---|---|---|
| UNITED STATES | 103 | 104 | 16 | 223 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2016 to primary completion in Jan 2019, 28 months.
Results were first posted in Feb 2020, 1 year after primary completion.
Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 28 months is below that.
Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenalidomide · Bortezomib · Dexamethasone
Janssen Research & Development, LLC →